Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Spruce Biosciences Inc (SPRB)

Spruce Biosciences Inc (SPRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 84,283
  • Shares Outstanding, K 1,070
  • Annual Sales, $ 4,910 K
  • Annual Income, $ -53,040 K
  • EBIT $ -49 M
  • EBITDA $ -49 M
  • 60-Month Beta 3.45
  • Price/Sales 17.16
  • Price/Cash Flow N/A
  • Price/Book 7.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -6.52
  • Number of Estimates 1
  • High Estimate -6.52
  • Low Estimate -6.52
  • Prior Year -42.86
  • Growth Rate Est. (year over year) +84.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
71.26 +16.22%
on 12/17/25
111.00 -25.39%
on 11/28/25
-22.18 (-21.12%)
since 11/21/25
3-Month
7.26 +1,040.77%
on 09/29/25
240.00 -65.49%
on 10/07/25
+73.74 (+812.11%)
since 09/22/25
52-Week
4.28 +1,837.31%
on 04/29/25
240.00 -65.49%
on 10/07/25
+52.82 (+176.07%)
since 12/20/24

Most Recent Stories

More News
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

Keli Walbert brings decades of commercial leadership experience and a proven track record of successful product launches in rare disease

SPRB : 82.82 (+5.18%)
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Granted Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfillipo Syndrome Type B (MPS IIIB) Biologics...

SPRB : 82.82 (+5.18%)
Spruce Biosciences Secures $50 Million Investment Deal

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Spruce Biosciences...

SPRB : 82.82 (+5.18%)
Spruce Biosciences Announces $50.0 Million Private Placement Financing

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...

SPRB : 82.82 (+5.18%)
Why This Microcap Biotech Stock Surged 1,378% in a Single Day

Shares of Spruce Biosciences (NASDAQ: SPRB) surged 1,378% to $130.40 on Monday after the U.S. Food and Drug Administration granted Breakthrough Therapy Designation (BTD) to tralesinidase alfa (TA-ERT)...

SPRB : 82.82 (+5.18%)
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Breakthrough Therapy Designation Supported by Integrated Long-Term Clinical Data Demonstrating Normalization in Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE) ...

SPRB : 82.82 (+5.18%)
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need,...

SPRB : 82.82 (+5.18%)
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrates Profound and Durable Efficacy and Safety in Patients with Sanfilippo...

SPRB : 82.82 (+5.18%)
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)

TA-ERT Profoundly and Durably Lowered Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE), the Factor Responsible for Neurodegeneration in MPS IIIB ...

SPRB : 82.82 (+5.18%)
Spruce Biosciences Announces Reverse Stock Split

Spruce’s Common Stock to Begin Trading on a Post-Split Adjusted Basis on August 5, 2025 Relisting on Nasdaq Capital Market Anticipated Following...

SPRB : 82.82 (+5.18%)

Business Summary

Spruce Biosciences Inc. is a biopharmaceutical company. It focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy which are in clinical stage. Spruce Biosciences Inc. is based in Daly City, California.

See More

Key Turning Points

3rd Resistance Point 90.21
2nd Resistance Point 86.59
1st Resistance Point 84.71
Last Price 82.82
1st Support Level 79.21
2nd Support Level 75.59
3rd Support Level 73.71

See More

52-Week High 240.00
Fibonacci 61.8% 149.95
Fibonacci 50% 122.14
Fibonacci 38.2% 94.32
Last Price 82.82
52-Week Low 4.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar